Related Experiment Video
Updated: Aug 24, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma
Mark S Duxbury1, Hiromichi Ito, Stanley W Ashley
1Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Immunotoxins are a potentially powerful approach for targeted anticancer therapy. We evaluated a novel immunotherapeutic strategy targeting the immunoglobulin superfamily member carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6). Using pancreatic adenocarcinoma as a model, we show that crosslinking CEACAM6 induces its cytoplasmic accumulation and that this effect can be utilized to increase the efficacy of antibody-mediated delivery of the ribosomal inhibitory protein saporin. Exposure of cells to anti-CEACAM6 antibody, followed by secondary saporin-conjugated immunoglobulin (IgG), induced marked cytotoxicity, via caspase-mediated apoptosis, in vitro. In an in vivo nude mouse xenograft model, this immunotherapeutic approach markedly suppressed pancreatic adenocarcinoma tumor growth and enhanced tumor apoptosis. Given the prevalence of CEACAM6 overexpression among human malignancies, immunological targeting of this tumor antigen may have therapeutic applicability.
Insights
Targeting carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) with immunotoxins shows promise for pancreatic cancer therapy. This novel approach effectively suppressed tumor growth and induced cancer cell death in preclinical models.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Immunotoxins offer a targeted approach for anticancer therapy.
- Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a potential target due to its overexpression in various cancers.
- Pancreatic adenocarcinoma serves as a relevant model for evaluating novel immunotherapies.
Purpose of the Study:
- To evaluate a novel immunotherapeutic strategy targeting CEACAM6 for pancreatic cancer.
- To investigate the efficacy of antibody-mediated delivery of saporin using CEACAM6 as a target.
- To assess the cytotoxic and tumor-suppressive effects of this approach in vitro and in vivo.
Main Methods:
- Utilizing pancreatic adenocarcinoma cells and a xenograft mouse model.
- Employing an anti-CEACAM6 antibody for targeted delivery of the ribosomal inhibitory protein saporin.
- Assessing cytotoxicity through caspase-mediated apoptosis assays.
- Evaluating tumor growth suppression and apoptosis induction in vivo.
Main Results:
- Crosslinking CEACAM6 led to its cytoplasmic accumulation.
- Anti-CEACAM6 antibody followed by saporin-conjugated IgG induced significant in vitro cytotoxicity via apoptosis.
- The immunotherapeutic approach markedly suppressed pancreatic adenocarcinoma tumor growth in vivo.
- Enhanced tumor apoptosis was observed in the in vivo model.
Conclusions:
- Targeting CEACAM6 with immunotoxins is a viable strategy for pancreatic cancer therapy.
- This approach demonstrates significant therapeutic potential due to its efficacy in inducing cancer cell death and suppressing tumor growth.
- The prevalence of CEACAM6 in malignancies suggests broad applicability for this immunological targeting strategy.
